Production and characterization of no-carrier-added 161Tb as an alternative to the clinically-applied 177Lu for radionuclide therapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2365-421X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Production and characterization of no-carrier-added 161Tb as an alternative to the clinically-applied 177Lu for radionuclide therapy ; volume:4 ; number:1 ; day:10 ; month:7 ; year:2019 ; pages:1-16 ; date:12.2019
EJNMMI radiopharmacy and chemistry ; 4, Heft 1 (10.7.2019), 1-16, 12.2019
- Urheber
-
Gracheva, Nadezda
Müller, Cristina
Talip, Zeynep
Heinitz, Stephan
Köster, Ulli
Zeevaart, Jan Rijn
Vögele, Alexander
Schibli, Roger
Van der Meulen, Nicholas P.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s41181-019-0063-6
- URN
-
urn:nbn:de:101:1-2019112210224029356301
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:04 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Gracheva, Nadezda
- Müller, Cristina
- Talip, Zeynep
- Heinitz, Stephan
- Köster, Ulli
- Zeevaart, Jan Rijn
- Vögele, Alexander
- Schibli, Roger
- Van der Meulen, Nicholas P.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Production of non carrier added (n.c.a.) 177Lu for radiopharmaceutical applications
Deadtime effects in quantification of 177Lu activity for radionuclide therapy
Simplified dosimetry for kidneys and tumors in 177Lu-labeled peptide receptor radionuclide therapy
Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates
Radionuclide generator-based production of therapeutic 177Lu from its long-lived isomer 177mLu
Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure
Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours
A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands
SPECT image segmentation for estimation of tumour volume and activity concentration in 177Lu-DOTATATE radionuclide therapy
Radionuclide
Correction to: Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure
Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy
Production of non carrier added (n.c.a.) 177Lu for radiopharmaceutical applications
Deadtime effects in quantification of 177Lu activity for radionuclide therapy
Simplified dosimetry for kidneys and tumors in 177Lu-labeled peptide receptor radionuclide therapy
Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates
Radionuclide generator-based production of therapeutic 177Lu from its long-lived isomer 177mLu
Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure
Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours
A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands
SPECT image segmentation for estimation of tumour volume and activity concentration in 177Lu-DOTATATE radionuclide therapy
Radionuclide
Correction to: Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure
Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy
Production of non carrier added (n.c.a.) 177Lu for radiopharmaceutical applications
Deadtime effects in quantification of 177Lu activity for radionuclide therapy
Simplified dosimetry for kidneys and tumors in 177Lu-labeled peptide receptor radionuclide therapy
Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates
Radionuclide generator-based production of therapeutic 177Lu from its long-lived isomer 177mLu
Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure
Radiation precautions for inpatient and outpatient 177Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours
A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands
SPECT image segmentation for estimation of tumour volume and activity concentration in 177Lu-DOTATATE radionuclide therapy
Radionuclide
Correction to: Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure